Halozyme Therapeutics (NASDAQ:HALO) COO Cortney Caudill Sells 20,000 Shares

Halozyme Therapeutics, Inc. (NASDAQ:HALO) COO Cortney Caudill sold 20,000 shares of the business’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $67.80, for a total transaction of $1,356,000.00. Following the transaction, the chief operating officer directly owned 14,366 shares of the company’s stock, valued at $974,014.80. The trade was a 58.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Cortney Caudill also recently made the following trade(s):

• On Tuesday, March 10th, Cortney Caudill sold 8,857 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $67.64, for a total value of $599,087.48.

Halozyme Therapeutics Stock Down 0.5%

HALO opened at $67.81 on Wednesday. Halozyme Therapeutics, Inc. has a 12 month low of $47.50 and a 12 month high of $82.22. The stock’s 50 day moving average price is $72.64 and its 200 day moving average price is $70.67. The company has a debt-to-equity ratio of 43.89, a current ratio of 4.66 and a quick ratio of 3.66. The stock has a market cap of $8.00 billion, a P/E ratio of 27.23, a P/E/G ratio of 0.28 and a beta of 0.98.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of $1.92 by ($2.16). The business had revenue of $451.77 million during the quarter, compared to analyst estimates of $446.13 million. Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. Halozyme Therapeutics’s revenue was up 51.6% compared to the same quarter last year. During the same period in the previous year, the company posted $1.26 earnings per share. As a group, research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of hedge funds have recently made changes to their positions in the business. CWM LLC boosted its holdings in Halozyme Therapeutics by 2,136.0% during the third quarter. CWM LLC now owns 23,881 shares of the biopharmaceutical company’s stock valued at $1,751,000 after purchasing an additional 22,813 shares in the last quarter. Arbor Investment Advisors LLC acquired a new stake in Halozyme Therapeutics in the 3rd quarter valued at $1,316,000. Monument Capital Management bought a new position in Halozyme Therapeutics in the 3rd quarter worth approximately $2,015,000. Pacer Advisors Inc. boosted its position in shares of Halozyme Therapeutics by 2,054.7% in the 3rd quarter. Pacer Advisors Inc. now owns 478,874 shares of the biopharmaceutical company’s stock worth $35,121,000 after purchasing an additional 456,649 shares during the last quarter. Finally, Cardinal Capital Management acquired a new stake in shares of Halozyme Therapeutics during the third quarter worth about $1,303,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on HALO shares. The Goldman Sachs Group reaffirmed a “sell” rating and issued a $56.00 price target on shares of Halozyme Therapeutics in a report on Thursday, December 4th. TD Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, January 29th. Benchmark raised their target price on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, February 19th. Finally, Wells Fargo & Company upped their price target on Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a report on Thursday, February 19th. Six investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $78.56.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.